Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b cli… Read more
Oculis Holding AG Ordinary shares (OCS) - Total Assets
Latest total assets as of September 2025: $167.84 Million USD
Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) holds total assets worth $167.84 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oculis Holding AG Ordinary shares - Total Assets Trend (2020–2024)
This chart illustrates how Oculis Holding AG Ordinary shares’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oculis Holding AG Ordinary shares - Asset Composition Analysis
Current Asset Composition (December 2024)
Oculis Holding AG Ordinary shares's total assets of $167.84 Million consist of 87.2% current assets and 12.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.0% |
| Accounts Receivable | $777.00K | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $13.29 Million | 11.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Oculis Holding AG Ordinary shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oculis Holding AG Ordinary shares's current assets represent 87.2% of total assets in 2024, an increase from 37.6% in 2020.
- Cash Position: Cash and equivalents constituted 23.0% of total assets in 2024, down from 30.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 53.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 11.0% of total assets.
Oculis Holding AG Ordinary shares Competitors by Total Assets
Key competitors of Oculis Holding AG Ordinary shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oculis Holding AG Ordinary shares - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oculis Holding AG Ordinary shares generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oculis Holding AG Ordinary shares is currently not profitable relative to its asset base.
Oculis Holding AG Ordinary shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.47 | 4.02 | 11.81 |
| Quick Ratio | 4.47 | 4.02 | 12.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $117.18 Million | $ 83.77 Million | $ 43.92 Million |
Oculis Holding AG Ordinary shares - Advanced Valuation Insights
This section examines the relationship between Oculis Holding AG Ordinary shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.74 |
| Latest Market Cap to Assets Ratio | 8.93 |
| Asset Growth Rate (YoY) | 5.2% |
| Total Assets | $120.35 Million |
| Market Capitalization | $1.07 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Oculis Holding AG Ordinary shares's assets at a significant premium ( 8.93x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Oculis Holding AG Ordinary shares's assets grew by 5.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Oculis Holding AG Ordinary shares (2020–2024)
The table below shows the annual total assets of Oculis Holding AG Ordinary shares from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $120.35 Million | +5.25% |
| 2023-12-31 | $114.35 Million | +208.56% |
| 2022-12-31 | $37.06 Million | -36.15% |
| 2021-12-31 | $58.04 Million | +254.29% |
| 2020-12-31 | $16.38 Million | -- |